British journal of cancer
-
British journal of cancer · Jul 2010
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine kinase inhibitor that has shown benefit in various other cancers. ⋯ Sunitinib is an active treatment for metastatic TC. A panel of molecular analyses may be warranted for optimal patient selection.